Release Primary Care Capacity with Home Testing
Raise adherence and improve kidney health outcomes by shifting testing from the clinic to the home.
Title Lorem ipsum
dolor sit amet
Job Title lorem ipsum
Job Title lorem ipsum
Job Title Lorem ipsum dolor sit amet
Add Your Heading Text Here
Add Your Heading Text Here
Blog Post
Lorem ipsum dolor sit amet
Webinar
Lorem ipsum dolor sit amet
Video
Lorem ipsum dolor sit amet
Title Lorem ipsum
dolor sit amet
Toggle ContentsdfsadfsdfsdfasdfsadfasdfContentsdfsadfsdfsdfasdfsadfasdfContentsdfsadfsdfsdfasdfsadfasdfContentsdfsadfsdfsdfasdfsadfasdfContentsdfsadfsdfsdfasdfsadfasdfContentsdfsadfsdfsdfasdfsadfasdfContentsdfsadfsdfsdfasdfsadfasdfContentsdfsadfsdfsdfasdfsadfasdf
Title Lorem ipsum
dolor sit amet
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Fully Funded Programmes in the South East
Healthy.io and NHS South East, in partnership with NHSx, the Accelerated Access Collaborative and the National Institute for Health Research, have received funding to help shift kidney health testing from the clinic to the home across the UK.
This nationally significant programme uses tried and tested technology to deliver a COVID safe service, which aims to improve outcomes in kidney health testing for people with diabetes and other cohorts at risk for chronic kidney disease. We are seeking immediate expressions of interest from PCNs, CCGs, STPs, and other providers which specialise in this area of healthcare.
Shifting testing to the patients’ home has shown to raise adherence to testing from 0% to 72% among consented untested patients, whilst minimising the traditional workload each practice has to take on to fulfil this care process.
Key Benefits
- Reduce backlogs in chronic disease management
- Help vulnerable patients stay at home
- Meet national guidelines around ACR testing
- Integrate results direct to the EPR
- Drive population health savings
- Address health inequalities by reaching untested populations
- Adopt a new testing model – free of charge
We send ACR test kits directly to eligible patients' homes with their prior consent
Patients self-test using our test kit and smartphone app, which guides them easily
Results are analysed and uploaded to SystmOne or EMIS workflows in real time
found the test 'easy' or 'very easy' to use
preferred testing at home vs. testing in the clinic
would recommend this service to a friend
Clinical-Grade Testing from Home
The CKD early detection service increases adherence to annual urinary albumin to creatinine ratio (ACR) testing, which is known to be beneficial in the early detection and prevention of CKD, is recommended by NICE, and monitored by the National Diabetes Audit.
The test is built around the existing ACR point of care dipstick. It measures semi quantitative analysis of microalbumin (10 – 150 mg/L), creatinine (10 – 300mg/dL) and albumin to creatinine ratio (mg/g).
Results are expressed as ACR normal (<30mg/g), ACR abnormal (30-300mg/g) or ACR high abnormal (>300mg/g).
The product is CE marked, GDPR compliant, and follows industry standards for privacy and safety.
Barking and Dagenham CCG
Call for Expressions of Interest
Fully funded deployments of the service are available to innovative, forward-thinking partners interested in empowering their patients and improving care through an evidence-based, time-saving, and patient-focused digital technology.
Expressions of interest submitted by February 19, 2021 will be processed first. Once submitted, we will be in touch to discuss the next steps towards releasing these benefits for your patient population at scale.
Please contact [email protected] with any questions.
By providing this information, you consent to receive relevant content from Healthy.io. (You may opt out at any point.) For more information, visit our Privacy Policy.
- Judith Shore, Michelle Green, Andrew Hardy & Deborah Livesey (2019): The compliance and cost-effectiveness of smartphone urinalysis albumin screening for people with diabetes in England, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2019.1650024
/* Video and Image block scripts: */